腾讯网8 天
JACC：家族性高胆固醇血症高危人群面临的五大挑战
他汀类药物、依折麦布和PCSK9抑制剂的出现极大改善了家族性高胆固醇血症（FH）的预后。然而，尽管进行了最大限度的降脂治疗，许多FH患者的低密度脂蛋白胆固醇（LDL-C）水平仍达不到指南推荐的水平。不依赖于低密度脂蛋白（LDL）受体活性而降低LDL的 ...
pharmaphorum7 天
Verve starts trials of cholesterol drug in test of base editing technique
Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot treatment.